AbbVie Reports Q3 2026 Revenue Beat Driven by Skyrizi and Rinvoq Growth
AbbVie (ABBV) reported third-quarter 2026 financial results that exceeded market expectations, posting $17.4 billion in revenue. The company's performance was bolstered by strong sales from its newer immunology portfolio, specifically Skyrizi and Rinvoq, which successfully mitigated the ongoing revenue decline caused by biosimilar competition for its former top-selling drug, Humira. The reported revenue represents approximately 10% year-over-year growth. Despite beating analyst estimates, the company's stock experienced downward pressure following the announcement, reflecting investor scrutiny over long-term transition dynamics and market expectations.
Tickers: $ABBV
Topics: immunology pharmaceuticals revenue
Read the full article at Seeking Alpha
Part of the story AMD Reports Record Q3 2026 Revenue Driven by Data Center Growth (12 articles)